PT2283817T - Método de fabrico de partículas para utilização numa composição farmacêutica - Google Patents

Método de fabrico de partículas para utilização numa composição farmacêutica

Info

Publication number
PT2283817T
PT2283817T PT101818995T PT10181899T PT2283817T PT 2283817 T PT2283817 T PT 2283817T PT 101818995 T PT101818995 T PT 101818995T PT 10181899 T PT10181899 T PT 10181899T PT 2283817 T PT2283817 T PT 2283817T
Authority
PT
Portugal
Prior art keywords
particles
pharmaceutical composition
manufacture
relates
composite active
Prior art date
Application number
PT101818995T
Other languages
English (en)
Inventor
Staniforth John
Michael James Green Matthew
Alexander Vodden Morton David
Original Assignee
Vectura Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31891809&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2283817(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0029261A external-priority patent/GB0029261D0/en
Priority claimed from GB0030946A external-priority patent/GB0030946D0/en
Priority claimed from PCT/GB2001/001606 external-priority patent/WO2001076575A2/en
Priority claimed from GB0124010A external-priority patent/GB0124010D0/en
Application filed by Vectura Ltd filed Critical Vectura Ltd
Publication of PT2283817T publication Critical patent/PT2283817T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5115—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/501—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT101818995T 2000-11-30 2001-11-30 Método de fabrico de partículas para utilização numa composição farmacêutica PT2283817T (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0029261A GB0029261D0 (en) 2000-11-30 2000-11-30 Method of making particles for use in a pharmaceutical composition
GB0030946A GB0030946D0 (en) 2000-12-19 2000-12-19 Method of making particles for use in a pharmaceutical composition
PCT/GB2001/001606 WO2001076575A2 (en) 2000-04-07 2001-04-09 The treatment of respiratory diseases
GB0124010A GB0124010D0 (en) 2001-10-05 2001-10-05 Pharmaceutical compositions for inhalation

Publications (1)

Publication Number Publication Date
PT2283817T true PT2283817T (pt) 2016-08-22

Family

ID=31891809

Family Applications (4)

Application Number Title Priority Date Filing Date
PT101818995T PT2283817T (pt) 2000-11-30 2001-11-30 Método de fabrico de partículas para utilização numa composição farmacêutica
PT101856433T PT2283818T (pt) 2000-11-30 2001-11-30 Método de preparação de partículas para utilização numa composição farmacêutica
PT01998328T PT1337240E (pt) 2000-11-30 2001-11-30 Método de fabrico de partículas para utilização numa composição farmacêutica
PT71239222T PT1920763E (pt) 2000-11-30 2001-11-30 Composições farmacêuticas para inalação

Family Applications After (3)

Application Number Title Priority Date Filing Date
PT101856433T PT2283818T (pt) 2000-11-30 2001-11-30 Método de preparação de partículas para utilização numa composição farmacêutica
PT01998328T PT1337240E (pt) 2000-11-30 2001-11-30 Método de fabrico de partículas para utilização numa composição farmacêutica
PT71239222T PT1920763E (pt) 2000-11-30 2001-11-30 Composições farmacêuticas para inalação

Country Status (9)

Country Link
US (11) US8048451B2 (pt)
EP (7) EP2283818B1 (pt)
JP (1) JP5192447B2 (pt)
AT (2) ATE517607T1 (pt)
CA (1) CA2429665C (pt)
CY (4) CY1112338T1 (pt)
DK (4) DK1920763T3 (pt)
ES (3) ES2587135T3 (pt)
PT (4) PT2283817T (pt)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9515182D0 (en) * 1995-07-24 1995-09-20 Co Ordinated Drug Dev Improvements in and relating to powders for use in dry powder inhalers
GB0009469D0 (en) * 2000-04-17 2000-06-07 Vectura Ltd Improvements in or relating to formalities for use in inhaler devices
PT1913939T (pt) 2000-06-27 2017-07-19 Vectura Ltd Formulações para utilização em dispositivos inalatórios
PT2283817T (pt) 2000-11-30 2016-08-22 Vectura Ltd Método de fabrico de partículas para utilização numa composição farmacêutica
AU2002220857A1 (en) * 2000-11-30 2002-06-11 Vectura Limited Particles for use in a pharmaceutical composition
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
US20060147389A1 (en) * 2004-04-14 2006-07-06 Vectura Ltd. Devices and pharmaceutical compositions for enhancing dosing efficiency
US20120321717A1 (en) * 2003-04-14 2012-12-20 Vectura Ltd. Devices and pharmaceutical compositions for enhancing dosing efficiency
GB0327723D0 (en) 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
GB0321607D0 (en) * 2003-09-15 2003-10-15 Vectura Ltd Manufacture of pharmaceutical compositions
US20050056958A1 (en) * 2003-09-16 2005-03-17 Eastman Kodak Company Forming homogeneous mixtures of organic materials for physical vapor deposition using dry mixing
GB0409703D0 (en) * 2004-04-30 2004-06-02 Vectura Ltd Pharmaceutical compositions
GB0418791D0 (en) 2004-08-23 2004-09-22 Glaxo Group Ltd Novel process
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
GB0426301D0 (en) * 2004-11-30 2004-12-29 Vectura Ltd Pharmaceutical formulations
US8623405B2 (en) * 2005-01-28 2014-01-07 Takeda Pharmaceutical Company Limited Finely divided composition containing poorly water soluble substance
US7951419B2 (en) 2005-07-21 2011-05-31 Multisorb Technologies, Inc. Dry-coated oxygen-scavenging particles and methods of making them
CA2631492A1 (en) * 2005-12-15 2007-06-21 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for oral administration
WO2008000042A1 (en) 2006-06-30 2008-01-03 Iceutica Pty Ltd Methods for the preparation of biologically active compounds in nanoparticulate form
US8969402B2 (en) 2006-11-15 2015-03-03 Steven A. Rich Combined acetylcholinesterase inhibitor and quaternary ammonium antimuscarinic therapy to alter progression of cognitive diseases
US7883039B2 (en) * 2007-02-27 2011-02-08 Collette Nv Continuous granulating and drying apparatus including measurement units
GB0712316D0 (en) * 2007-06-26 2007-08-01 Entripneur Ltd A novel powder and its method of manufacture
EP2234595B1 (en) * 2007-12-13 2012-11-28 Novartis AG Process for reducing the tendency of a glycopyyronium salt to aggegate during storage.
US20100266696A1 (en) * 2007-12-13 2010-10-21 Gerhard Muhrer Organic Compounds
WO2010014846A1 (en) * 2008-07-30 2010-02-04 T & T Enterprises Inc. Antioxidant additive
JP5809985B2 (ja) 2009-02-26 2015-11-11 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ ４−｛（１ｒ）−２−［（６−｛２−［（２，６−ジクロロベンジル）オキシ］エトキシ｝ヘキシル）アミノ］−１−ヒドロキシエチル｝−２−（ヒドロキシメチル）フェノールを含む医薬製剤
MX354829B (es) 2009-03-26 2018-03-22 Pulmatrix Operating Co Inc Formulaciones de polvo seco y metodos para el tratamiento de enfermedades pulmonares.
IL254370B2 (en) * 2009-04-24 2023-12-01 Iceutica Pty Ltd Production of coated nanoparticles with a high particle volume
UA106231C2 (uk) 2009-04-24 2014-08-11 Айсьютика Пти Лтд Разова доза фармацевтичної композиції індометацину (варіанти)
AU2010239161B2 (en) * 2009-04-24 2014-10-09 Iceutica Pty Ltd Production of encapsulated nanoparticles at commercial scale
AU2010253770B9 (en) 2009-05-29 2015-02-12 Pearl Therapeutics, Inc. Compositions for respiratory delivery of active agents and associated methods and systems
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
GB0921075D0 (en) 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
US8715770B2 (en) * 2010-03-09 2014-05-06 Stc.Unm Apparatuses and methods for microparticle dry coating of surfaces
CA2809666C (en) * 2010-08-30 2020-09-22 Michael M. Lipp Dry powder formulations and methods for treating pulmonary diseases
EP2464346A1 (en) 2010-08-30 2012-06-20 Pulmatrix, Inc. Treatment of cystic fibrosis using calcium lactate, leucine and sodium chloride in a respiraple dry powder
AU2011314007B2 (en) 2010-09-29 2017-01-19 Pulmatrix, Inc. Cationic dry powders
RU2640921C2 (ru) 2010-09-29 2018-01-12 Пулмэтрикс, Инк. Катионы одновалентных металлов сухих порошков для ингаляций
WO2013128283A2 (en) * 2012-02-28 2013-09-06 Iceutica Holdings Inc. Bvi Inhalable pharmaceutical compositions
JP2015509788A (ja) 2012-02-29 2015-04-02 パルマトリックス，インコーポレイテッド 吸入に適した乾燥粉末
MX366744B (es) * 2012-03-23 2019-06-28 Copamex S A De C V Composición super-hidrofóbica, su preparación y papel que presenta super-hidrofobicidad.
US9763965B2 (en) 2012-04-13 2017-09-19 Glaxosmithkline Intellectual Property Development Limited Aggregate particles
CN105050708A (zh) 2012-11-14 2015-11-11 格雷斯公司 含有生物活性材料与无序无机氧化物的组合物
US20140275517A1 (en) 2013-03-15 2014-09-18 Pearl Therapeutics, Inc. Methods and systems for conditioning of particulate crystalline materials
CA2907566C (en) 2013-04-01 2023-08-22 Pulmatrix, Inc. Tiotropium dry powders
SI3569222T1 (sl) * 2013-07-11 2024-10-30 Chiesi Farmaceutici S.P.A. Formulacija suhega praška, obsegajoča antiholinergik, kortikosteroid in beta-adrenergik, za dajanje z inhalacijo
GB201402513D0 (en) * 2014-02-13 2014-04-02 Cardiff Scintigraphics Ltd Pressurised metered dose inhalers and method of manufacture
US9526734B2 (en) 2014-06-09 2016-12-27 Iceutica Pty Ltd. Formulation of meloxicam
AU2015338717B2 (en) 2014-10-31 2018-12-20 Glaxosmithkline Intellectual Property Development Limited Powder formulation
MA41378A (fr) * 2015-01-20 2017-11-28 Teva Branded Pharmaceutical Prod R & D Inc Inhalateur de poudre sèche comprenant du propionate de fluticasone et du xinafoate de salmétérol
WO2016204998A1 (en) * 2015-06-15 2016-12-22 Qaam Pharmaceuticals, Llc Glycopyrronium fatty acid salts and methods of making same
WO2020047228A1 (en) * 2018-08-30 2020-03-05 HYDRO-QUéBEC Coated lithium ion rechargeable battery active materials
US10966943B2 (en) 2018-09-06 2021-04-06 Innopharmascreen Inc. Methods and compositions for treatment of asthma or parkinson's disease
US12269041B2 (en) 2019-09-19 2025-04-08 New Jersey Institute Of Technology Spherical composite powder
US12109202B2 (en) 2021-01-29 2024-10-08 Qaam Pharmaceuticals, Llc Fixed dose combination of cholinesterase inhibitor and a quaternary ammonium antimuscarinic agent to treat neurodegenerative cognitive disorders
JP2024125434A (ja) * 2021-07-20 2024-09-19 興和株式会社 新規吸入剤
CN119278026A (zh) 2022-03-31 2025-01-07 好利安科技有限公司 吸入复合材料和基于载体的制剂组合
KR20250053839A (ko) 2022-06-21 2025-04-22 호비온 사이언티아 리미티드 당과 지질 복합입자를 포함하는 흡입용 결정형 약학 조성물 및 제조방법
US20250387327A1 (en) 2022-07-04 2025-12-25 Hovione Scientia Limited Dry powder inhaler pharmaceutical composition of coated crystalline dry powder for inhalation

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1240092A (en) 1970-01-08 1971-07-21 Dynamic Tools Ltd A swivel connector
GB1381872A (en) 1971-06-22 1975-01-29 Fisons Ltd Pharmaceutical compositions for inhalation
US5192528A (en) 1985-05-22 1993-03-09 Liposome Technology, Inc. Corticosteroid inhalation treatment method
IT1204826B (it) * 1986-03-04 1989-03-10 Chiesi Farma Spa Composizioni farmaceutiche per inalazione
PT85521B (pt) * 1986-08-11 1990-06-29 Innovata Biomed Ltd Processo para a preparacao de composicoes farmaceuticas que consistem em microcapsulas
US5320906A (en) * 1986-12-15 1994-06-14 Vestar, Inc. Delivery vehicles with amphiphile-associated active ingredient
JP2668880B2 (ja) 1987-06-23 1997-10-27 日本油脂株式会社 被覆アミノ酸類の製造方法
US5190764A (en) 1988-03-03 1993-03-02 Hokko Chemical Industry Co., Ltd. Agent for imparting a sustained release property to a pesticide, a pesticide having a sustained release property and a process for the production thereof
US5223244A (en) 1988-06-20 1993-06-29 Shiseido Company, Ltd. Aerosol composition
US4906476A (en) 1988-12-14 1990-03-06 Liposome Technology, Inc. Novel liposome composition for sustained release of steroidal drugs in lungs
EP0470154B1 (en) * 1989-04-28 1996-06-05 Riker Laboratories, Inc. Dry powder inhalation device
US5188837A (en) * 1989-11-13 1993-02-23 Nova Pharmaceutical Corporation Lipsopheres for controlled delivery of substances
US5376386A (en) 1990-01-24 1994-12-27 British Technology Group Limited Aerosol carriers
IL98310A (en) 1990-06-08 1996-08-04 Astra Ab Pharmaceutical compositions comprising cystine derivatives
GB9024365D0 (en) 1990-11-09 1991-01-02 Glaxo Group Ltd Medicaments
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5413804A (en) 1991-04-23 1995-05-09 Cacique, Inc. Process for making whey-derived fat substitute product and products thereof
DE4140689B4 (de) 1991-12-10 2007-11-22 Boehringer Ingelheim Kg Inhalationspulver und Verfahren zu ihrer Herstellung
JP2735979B2 (ja) * 1992-04-23 1998-04-02 花王株式会社 樹脂粉末及び化粧料
EP0611567B1 (en) * 1992-06-12 2002-08-28 Teijin Limited Ultrafine powder for inhalation and production thereof
GB2269992A (en) 1992-08-14 1994-03-02 Rh Ne Poulenc Rorer Limited Powder inhalation formulations
JPH0696517A (ja) 1992-09-11 1994-04-08 Matsushita Electric Ind Co Ltd 磁気ディスク装置
SE9203743D0 (sv) * 1992-12-11 1992-12-11 Astra Ab Efficient use
US5672581A (en) 1993-01-29 1997-09-30 Aradigm Corporation Method of administration of insulin
TW402506B (en) 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation
US5506203C1 (en) * 1993-06-24 2001-02-06 Astra Ab Systemic administration of a therapeutic preparation
DE4323636A1 (de) * 1993-07-15 1995-01-19 Hoechst Ag Arzneistoffzubereitungen aus umhüllten, schwerstwasserlöslichen Arzneistoffen für Inhalationsarzneiformen und Verfahren zu ihrer Herstellung
US5744155A (en) 1993-08-13 1998-04-28 Friedman; Doron Bioadhesive emulsion preparations for enhanced drug delivery
GB9322014D0 (en) 1993-10-26 1993-12-15 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
US5441753A (en) * 1994-01-28 1995-08-15 Fmc Corporation Coprocessed particulate bulking and formulating AIDS: their composition, production, and use
ES2218543T3 (es) * 1994-03-07 2004-11-16 Nektar Therapeutics Procedimiento y preparacion para la administracion de insulina por via pulmonar.
US5711934A (en) * 1994-04-11 1998-01-27 Abbott Laboratories Process for the continuous milling of aerosol pharmaceutical formulations in aerosol propellants
US5647347A (en) 1994-10-21 1997-07-15 Glaxo Wellcome Inc. Medicament carrier for dry powder inhalator
US6103271A (en) * 1994-12-02 2000-08-15 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Microencapsulation and electrostatic processing method
US6524557B1 (en) 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
WO1996019198A1 (en) * 1994-12-22 1996-06-27 Astra Aktiebolag Aerosol drug formulations
SA95160463B1 (ar) 1994-12-22 2005-10-04 استرا أكتيبولاج مساحيق للاستنشاق
GB9501841D0 (en) * 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
US5612053A (en) 1995-04-07 1997-03-18 Edward Mendell Co., Inc. Controlled release insufflation carrier for medicaments
US5635160A (en) * 1995-06-07 1997-06-03 The University Of North Carolina At Chapel Hill Dinucleotides useful for the treatment of cystic fibrosis and for hydrating mucus secretions
US5931809A (en) 1995-07-14 1999-08-03 Depotech Corporation Epidural administration of therapeutic compounds with sustained rate of release
GB9515182D0 (en) 1995-07-24 1995-09-20 Co Ordinated Drug Dev Improvements in and relating to powders for use in dry powder inhalers
SE9502799D0 (sv) 1995-08-10 1995-08-10 Astra Ab Device in inhalers
US5738665A (en) 1996-09-26 1998-04-14 Becton, Dickinson And Company Shield and actuator for needles
US7366670B1 (en) 1997-08-05 2008-04-29 At&T Corp. Method and system for aligning natural and synthetic video to speech synthesis
US5997846A (en) 1997-11-17 1999-12-07 Albert Einstein College Of Medicine Of Yeshiva University Method for detecting arthropods
US6178414B1 (en) * 1997-12-16 2001-01-23 Nortel Networks Limited Method and apparatus for updating and searching an ordered list of values stored within a memory resource
US6086376A (en) 1998-01-30 2000-07-11 Rtp Pharma Inc. Dry aerosol suspension of phospholipid-stabilized drug microparticles in a hydrofluoroalkane propellant
US20030118514A1 (en) * 1998-03-26 2003-06-26 Glaxo Wellcome Inc. Compositions for inhalation
US5945123A (en) 1998-04-02 1999-08-31 K-V Pharmaceutical Company Maximizing effectiveness of substances used to improve health and well being
DK1073417T3 (da) † 1998-04-18 2003-03-24 Glaxo Group Ltd Farmaceutisk aerosolformulering
GT199900148A (es) * 1998-09-10 2001-02-28 Desnaturalizantes para las sales aminas simpaticomimeticas.
US7521068B2 (en) * 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
DK1283036T3 (da) † 1998-11-13 2008-03-25 Jagotec Ag Törpulver til inhalation
US20070212422A1 (en) * 1999-11-10 2007-09-13 Manfred Keller Dry powder for inhalation
US20010020242A1 (en) * 1998-11-16 2001-09-06 Amit Gupta Method and apparatus for processing client information
HUP0104687A3 (en) * 1998-11-18 2006-07-28 Univ Florida Methods for preparing coated drug particles and pharmaceutical formulations thereof
US6984404B1 (en) 1998-11-18 2006-01-10 University Of Florida Research Foundation, Inc. Methods for preparing coated drug particles and pharmaceutical formulations thereof
GB9826783D0 (en) 1998-12-04 1999-01-27 Scherer Ltd R P Inhalation powders
GB9827145D0 (en) 1998-12-09 1999-02-03 Co Ordinated Drug Dev Improvements in or relating to powders
US6542490B1 (en) * 1999-01-29 2003-04-01 Nortel Networks Limited Data link control proctocol for 3G wireless system
IT1309592B1 (it) 1999-03-05 2002-01-24 Chiesi Farma Spa Particelle veicolo modificate da utilizzarsi nella preparazione diformulazioni farmaceutiche sotto forma di polimeri per inalazione e
PL196951B1 (pl) 1999-03-05 2008-02-29 Chiesi Farma Spa Proszek do stosowania w inhalatorze suchego proszku, cząsteczki nośnika i sposób wytwarzania nośnika
ES2193069T3 (es) * 1999-04-14 2003-11-01 Glaxo Group Ltd Formulacion farmaceutica en aerosol.
US6406745B1 (en) 1999-06-07 2002-06-18 Nanosphere, Inc. Methods for coating particles and particles produced thereby
ITMI991582A1 (it) 1999-07-16 2001-01-16 Chiesi Farma Spa Polveri costituite da particelle aventi la superficie perfettamente levigata da utilizzare come veicoli per la preparazione di miscele inala
US6197369B1 (en) * 1999-09-30 2001-03-06 New Jersey Institute Of Technology Method of particle coating
GB0008660D0 (en) 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
GB0009469D0 (en) 2000-04-17 2000-06-07 Vectura Ltd Improvements in or relating to formalities for use in inhaler devices
PE20011227A1 (es) * 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
GB0009468D0 (en) 2000-04-17 2000-06-07 Vectura Ltd Improvements in or relating to formulations for use in inhaler devices
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
PT1913939T (pt) 2000-06-27 2017-07-19 Vectura Ltd Formulações para utilização em dispositivos inalatórios
US6404772B1 (en) 2000-07-27 2002-06-11 Symbol Technologies, Inc. Voice and data wireless communications network and method
ATE320242T1 (de) 2000-10-09 2006-04-15 3M Innovative Properties Co Medizinische aerosolzusammensetzung
PL200063B1 (pl) 2000-10-12 2008-12-31 Boehringer Ingelheim Pharma Nowe proszki do inhalacji zawierające tiotropium
PT2283817T (pt) * 2000-11-30 2016-08-22 Vectura Ltd Método de fabrico de partículas para utilização numa composição farmacêutica
AU2002220857A1 (en) * 2000-11-30 2002-06-11 Vectura Limited Particles for use in a pharmaceutical composition
US20060147389A1 (en) 2004-04-14 2006-07-06 Vectura Ltd. Devices and pharmaceutical compositions for enhancing dosing efficiency
US20060292081A1 (en) 2003-09-15 2006-12-28 Vectura Limited Methods for preparing pharmaceutical compositions
GB0321607D0 (en) * 2003-09-15 2003-10-15 Vectura Ltd Manufacture of pharmaceutical compositions
GB0425758D0 (en) * 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
GB0426301D0 (en) * 2004-11-30 2004-12-29 Vectura Ltd Pharmaceutical formulations
CA2784207C (en) * 2009-12-14 2018-06-05 Chiesi Farmaceutici S.P.A. Antibiotic microparticles for inhalation

Also Published As

Publication number Publication date
EP2283817B1 (en) 2016-05-18
EP2298279A2 (en) 2011-03-23
JP5192447B2 (ja) 2013-05-08
US20160243046A1 (en) 2016-08-25
ATE382335T1 (de) 2008-01-15
EP2283818B1 (en) 2017-08-02
US7736670B2 (en) 2010-06-15
EP1337240B1 (en) 2011-07-27
CY1115304T1 (el) 2017-01-04
EP2298279A3 (en) 2011-08-03
US8932635B2 (en) 2015-01-13
DK2283818T3 (en) 2017-10-16
EP1920763B2 (en) 2022-06-15
PT1337240E (pt) 2011-11-02
US20100209358A1 (en) 2010-08-19
EP2298285A3 (en) 2011-07-27
EP1920763B1 (en) 2014-04-02
US8956661B2 (en) 2015-02-17
US20130017267A1 (en) 2013-01-17
PT2283818T (pt) 2017-10-09
DK1337240T3 (da) 2011-11-21
HK1058145A1 (en) 2004-05-07
CY1119400T1 (el) 2018-02-14
ATE517607T1 (de) 2011-08-15
CA2429665C (en) 2013-10-22
US20040037785A1 (en) 2004-02-26
US20150086640A1 (en) 2015-03-26
CY1112338T1 (el) 2015-12-09
US8303991B2 (en) 2012-11-06
EP1337240B2 (en) 2014-09-24
US9962338B2 (en) 2018-05-08
US10188612B2 (en) 2019-01-29
EP2298285A2 (en) 2011-03-23
EP3269360A1 (en) 2018-01-17
US20150079185A1 (en) 2015-03-19
EP2283818A1 (en) 2011-02-16
EP2283817A1 (en) 2011-02-16
PT1920763E (pt) 2014-06-25
US8048451B2 (en) 2011-11-01
JP2009242408A (ja) 2009-10-22
US20170266122A1 (en) 2017-09-21
DK1920763T3 (da) 2014-07-07
US20130344156A1 (en) 2013-12-26
US20120027863A1 (en) 2012-02-02
EP2298279B1 (en) 2018-11-14
US10973771B2 (en) 2021-04-13
DK2283817T3 (en) 2016-09-05
CA2429665A1 (en) 2002-06-06
HK1154347A1 (en) 2012-04-20
US20170172947A1 (en) 2017-06-22
DK1337240T4 (en) 2015-01-05
ES2587135T3 (es) 2016-10-20
US9931304B2 (en) 2018-04-03
US20040047810A1 (en) 2004-03-11
CY1117749T1 (el) 2017-05-17
ES2474199T3 (es) 2014-07-08
US10449161B2 (en) 2019-10-22
ES2708961T3 (es) 2019-04-12
US8435567B2 (en) 2013-05-07
EP1337240A2 (en) 2003-08-27
EP1920763A1 (en) 2008-05-14

Similar Documents

Publication Publication Date Title
PT1920763E (pt) Composições farmacêuticas para inalação
WO2002043701A3 (en) Method of making particles for use in a pharmaceutical composition
PT1913939T (pt) Formulações para utilização em dispositivos inalatórios
ATE271383T1 (de) Pulverformulierung zur inhalation
WO2005025536A8 (en) Dry powder composition comprising co-jet milled particles for pulmonary inhalation
BR0016879A (pt) Métodos para transferência de interleucina-2 por via pulmonar
NO20024708L (no) Behandling av respiratoriske sykdommer
CY1116272T1 (el) Φαρμακευτικα σκευασματα που περιεχουν μεθυλναλτρεξονη
PT1131071E (pt) Composicoes farmaceuticas contendo nicotina dando uma absorcao por via transmucosa rapida
AR060931A1 (es) Producto farmaceutico recubierto para la administracion intraoral de nicotina y su uso y elaboracion
ATE529126T1 (de) Stabilisierte pharmazeutische peptid zusammensetzungen
CY1110913T1 (el) Παραγωγα 2-πυρρολιδιν-2-υλο-[1,3,4]-οξαδιαζολης και η χρησιμοποιηση τους σαν αντικαταθλιπτικα
SE0103211D0 (sv) New formulations and use thereof
PH12015500301B1 (en) A novel formulation of diclofenac
UA87655C2 (ru) Получение стерильных композиций в форме водных суспензий, содержащих микронизированные кристаллические активные ингредиенты, для ингаляций
BRPI0608791B8 (pt) cápsulas para inaladores, uso de uma composição de polímero e processo para a secagem de pós para inalação
BR0307518A (pt) Composição farmacêutica
WO2006118948A3 (en) Therapeutic compositions
WO2007059931A8 (en) New adjuvants on the basis of bisacyloxypropylcysteine conjugates and derivatives and their uses in pharmaceutical compositions
WO2005041922A3 (en) Composition
DE602006011127D1 (de) Fettsäure-benzenediol-derivate sowie herstellungs- und verwendungsverfahren dafür
BR0315885A (pt) Processo para transformar uma matéria-prima base de goma incompressìvel em uma composição base de goma em pó compressìvel, composição base de goma, uso da mesma, goma de mascar, e, processo para a prepração de um produto da mesma
ECSP055821A (es) Nueva formulacion pulverulenta que contiene tiotropio destinado a la inhalación
CR9800A (es) Formas y composiciones de dosificaciones farmaceuticas
WO2005011615A3 (en) Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anticholinergic bronchodilator for treatment of asthma or chronic obstructive pulmonary disease